Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$216.34M+16503.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vikram Karnani
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 423
- Beta
- 0.73
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.92
Financials
Revenue
$216.34M+16503.1%Net Income
$21.76MEBITDA
$29.85MFree Cash Flow
$86.26MEPS (diluted)
$0.60Shares Outstanding (diluted)
39.11M+44.3%Operating Expenses
$99.59MCash & Debt
$144.80MReturn of Capital
$50.00MRevenue by Segment (annual)
$617.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $780.57M | $62.87M | $1.98 |
| 2024 | $631.45M | $69.19M | $2.14 |
| 2023 | $566.77M | $48.16M | $1.60 |
| 2022 | $463.93M | $-25.00M | $-0.74 |
| 2021 | $276.87M | $71.52M | $2.05 |
| 2020 | $310.02M | $26.75M | $0.78 |
| 2019 | $296.70M | $-22.72M | $-0.24 |
| 2018 | $280.41M | $-39.13M | $-1.19 |
| 2017 | $28.48M | $-74.86M | $-2.47 |
| 2016 | $1.71M | $-94.18M | $-3.88 |
| 2015 | $0.00 | $-27.25M | $-2.01 |
| 2014 | $0.00 | $-17.92M | $-2.40 |
| 2013 | $0.00 | $-16.20M | $-2.17 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.91
- Implied price
- $67.01
- Return from $24.72
- 22.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $33.32 — today's price is already 25.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -2.0% | 4.3% | 7.7% | 10.8% | 13.5% | 16.0% |
| 3.0% | 9.6% | 13.2% | 16.4% | 19.3% | 21.9% |
| 8.0% | 14.9% | 18.7% | 22.1% | 25.1% | 27.9% |
| 13.0% | 20.2% | 24.2% | 27.7% | 30.9% | 33.8% |
| 18.0% | 25.6% | 29.7% | 33.4% | 36.7% | 39.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (12)
- Newsseekingalpha.com·15d ago·Positive
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive VP & CFO Conference Call Participants Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, …
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurcha
View source ↗ - Newszacks.com·18d ago·Negative
COLL or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·24d ago·Neutral
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
…legium to Report Third Quarter 2026 Financial Results on November 5, 2026 STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a li…
View source ↗ - Newszacks.com·34d ago·Negative
COLL vs. DSNKY: Which Stock Is the Better Value Option? Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
View source ↗ - Newsseekingalpha.com·36d ago·Negative
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account for over 30% of 2026 sales, are growing robustly, and enjoy patent protection into the 2030s. Pain franchise decline is staged, with Nucynta facing immediate generic pressure, Belbuca's patent risk centered on an April 2027 t
View source ↗ - Newszacks.com·37d ago·Positive
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
…ractical Support to Help Families Navigate Care, School and Everyday Life STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
View source ↗ - Newsglobenewswire.com·101d ago·Negative
Collegium Announces $50 Million Accelerated Share Repurchase Program STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR a…
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $1.85 per share
Typical surprise +5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.96 vs $1.86beat
- Thu, Aug 6$1.92 vs $1.72beat
- Thu, May 7$1.76 vs $1.52beat
- Thu, Feb 26$2.04 vs $2.14miss
- Thu, Nov 6$2.25 vs $1.86beat
- Thu, Aug 7$1.68 vs $1.62beat
Estimates and results for COLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COLL officers and directors.
- Bought
- —
- Sold
- $15.4m
0 trades
37 trades
- Freund John Gordonsold
- Freund John Gordonsold
- Lurker Nancysold
- Bohlin Garen Gsold
- Dieter Davidsold
- Dieter Davidsold
- Dreyer Scottsold
- Dreyer Scottsold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in COLL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
